---
search:
  boost: 2 
---

# Unspecified GI

This is a subcategory of Gastrointestinal Agents.

## Formulary

### Preferred

| Preferred                          | Generic Name                  | Quantity | Time (Days) |
|:-----------------------------------|:------------------------------|:--------:|:-----------:|
| Amitiza <sup>BvG ST</sup>          |                               |          |             |
| Bisacodyl                          |                               |          |             |
| Casanthranol / Docusate Sodium     |                               |          |             |
| Dicyclomine                        |                               |          |             |
| Diphenoxylate / Atropine           |                               |          |             |
| Lactulose                          |                               |          |             |
| Linzess <sup>ST</sup> 145, 290 MCG |                               |          |             |
| Loperamide                         | Loperamide HCI Cap & Tab 2 MG |    80    |     34      |
| Movantik <sup>ST</sup>             |                               |          |             |
| Polyethylene Glycol                |                               |          |             |
| Psyllium Fiber                     |                               |          |             |
| Senna                              |                               |          |             |
| Trulance <sup>ST</sup>             |                               |          |             |
| Xifaxan <sup>ST</sup>              |                               |          |             |

### Non-Preferred

| Non-Preferred  | Generic Name | Quantity | Time (Days) |
|:---------------|:-------------|:--------:|:-----------:|
| Aemcolo        |              |          |             |
| Gattex         |              |          |             |
| Ibsrela        |              |          |             |
| Linzess 72 MCG |              |          |             |
| Lubiprostone   |              |          |             |
| Motegrity      |              |          |             |
| Mytesi         |              |          |             |
| Relistor       |              |          |             |
| Symproic       |              |          |             |
| Zorbtive       |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days except 3 days for Aemcolo

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Step Therapy

Step Therapy Approval Criteria

- Must have had an inadequate clinical response to at least **14 days** with at least **two preferred** drugs

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **three preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Methylnaltrexone (Relistor) and Naldemedine (Symproic)

Additional Methylnaltrexone (Relistor) and Naldemedine (Symproic) Criteria

- Must have a history of chronic pain requiring continuous opioid therapy for â‰¥84 days

### Rifamycin Delayed-Release (Aemcolo)

Additional Rifamycin Delayed-Release (Aemcolo) Criteria

Must have the inability to take, or failure of **ALL** of the following: azithromycin,
ciprofloxacin, levofloxacin, ofloxacin, or rifaximin

### Somatropin Injection (Zorbtive) and Tedloglutide (Gattex)

Additional Somatropin Injection (Zorbtive) and Tedloglutide (Gattex) Criteria

- Must have evidence of specialized parenteral nutritional support
- Must have documentation of appropriate lab assessment (bilirubin, alkaline phosphatase, lipase, and amylase) at least 180 days prior to initiation

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring (i.e., decreased frequency of specialized nutrition support or improvement in symptoms)

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=70)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=24)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
